Soligenix expands dilutive ATM offering by $2.5M, total program now $8.9M
SNGX sits 48% above its 52-week low of $0.28 on light trading volume (0.1× avg).
Summary
Soligenix increased its At-The-Market (ATM) offering capacity by an additional $2.5 million, bringing the total potential capital raise under the program to $8.9 million. This highly dilutive financing follows a series of negative events, including a Nasdaq delisting notice, a going concern warning, and the termination of its lead drug development program due to futility. The $2.5 million increase represents a substantial portion of the company's current market capitalization, underscoring severe financial distress and a continued reliance on equity sales to fund operations. The company had nearly exhausted its previous ATM capacity of $6.4 million.
At the time of this announcement, SNGX was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.28 to $6.23. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.